J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer

被引：6
|
作者：
Gainor, Justin F. [1 ]
Shaw, Alice T. [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
来源：
LANCET | 2017年 / 390卷 / 10089期
关键词：
PROGRESSION-FREE; OPEN-LABEL; CHEMOTHERAPY; CERITINIB; SURVIVAL;
D O I：
10.1016/S0140-6736(17)31074-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [1] Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
    Nishio, Makoto
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Tanaka, Tomohiro
    Kuriki, Hiroshi
    Zeaiter, Ali
    Tamura, Tomohide
    LUNG CANCER, 2018, 121 : 37 - 40
  • [2] Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
    Nakagawa, Kazuhiko
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Azuma, Koichi
    Kim, Young Hak
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Koyama, Ryo
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Asakawa, Takashi
    Hayashi, Morihiko
    Hasegawa, Wakako
    Tamura, Tomohide
    LUNG CANCER, 2020, 139 : 195 - 199
  • [3] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Shukuya, Takehito
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Asakawa, Takashi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    LANCET, 2017, 390 (10089): : 29 - 39
  • [4] Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)
    Kim, Young
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S378 - S379
  • [5] Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC): Primary results from the J-ALEX study.
    Nokihara, Hiroshi
    Hida, Toyoaki
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Jo, Makoto Nish
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer (vol 121, pg 37, 2018)
    Nishio, Makoto
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Tanaka, Tomohiro
    Kuriki, Hiroshi
    Zeaiter, Ali
    Tamura, Tomohide
    LUNG CANCER, 2019, 132 : 160 - 160
  • [7] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
  • [8] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
    Yoshioka, Hiroshige
    Hida, Toyoaki
    Nokihara, Hiroshi
    Morise, Masahiro
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Kumagai, Toru
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Yoshimoto, Takuya
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Crizotinib in ALK-positive lung cancer
    Girard, Nicolas
    LANCET ONCOLOGY, 2012, 13 (10): : 962 - 963
  • [10] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, Lucio
    Ahn, Myung-Ju
    De Pas, Tommaso
    Besse, Benjamin
    Solomon, Benjamin J.
    Blackhall, Fiona
    Wu, Yi-Long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. Ross
    Mok, Tony
    Hirsh, Vera
    Riely, Gregory J.
    Iyer, Shrividya
    Tassell, Vanessa
    Polli, Anna
    Wilner, Keith D.
    Jaenne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25): : 2385 - 2394
12345